BioPharma Dive 30. März 2026 United rises on IPF data; Biogen scores positive lupus data and an approval
BioPharma Dive 26. März 2026 Merck’s deal for Terns sparks debate over a possible biotech bidding war
BioPharma Dive 24. März 2026 Gilead, with Ouro deal, wagers $1.7B on bispecifics for autoimmune diseases